The Breakthrough Therapy designation is supported by data from the randomized, double-blind phase 3 HERCULES trial.
The FDA bestows a Breakthrough Therapy designation to Sanofi's tolebrutinib for treating non-relapsing secondary progressive multiple sclerosis.
The FDA has granted Breakthrough Therapy designation to tolebrutinib for treating adults with non-relapsing secondary ...
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of ...
The US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to tolebrutinib for the treatment of adults with non-relapsing secondary progressive multiple sclerosis (nrSPMS).
Paris: Sanofi has announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation to ...
Berger specialized in cancer long before joining Genentech, holding oncology global clinical development roles at Amgen and ...
French drug major Sanofi (SNY) announced Friday that the U.S. Food and Drug Administration has granted Breakthrough Therapy ...
Tolebrutinib designated Breakthrough Therapy by the FDA for non-relapsing secondary progressive multiple sclerosisDesignation is based on ...
The out-of-pocket cost for MS disease-modifying therapies jump by 217% going from $750 per year in 2012 to $2,378 per year in ...
Thomas Kudsk: Welcome to the Q3 2024 Conference Call for Investors and Analysts. As usual, you can find the slides on sanofi.com. Please turn to slide number three.
Sanofi is preparing a new vaccine and biopharmaceutical manufacturing facility in Singapore, located at Tuas Biomedical Park, Bloomberg reported Nov. 27. The plant, dubbed Modulus, represents an ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback